| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| TRAIL R1 | Human TRAIL R1 / DR4 / TNFRSF10A Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug | ||
| TRAIL R1 | Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
| HLX56 | HLX56; HLX-56 | Phase 1 Clinical | Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特, Shaite | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | Details |
